Tirzepatide's shortage-list status closed on December 19, 2024, when the FDA issued a declaratory order affirming the shortage was resolved. The compliance runway many compounding pharmacies relied on has narrowed since. The FDA has proposed excluding tirzepatide, along with semaglutide and liraglutide, from the 503B Bulks List entirely, and Eli Lilly has filed a litigation campaign against compounding pharmacies and telehealth platforms it accuses of marketing mass-produced tirzepatide as personalized medicine. For a compounding pharmacist still dispensing tirzepatide formulations, the exposure now runs on three tracks: FDA enforcement, manufacturer litigation, and state board scrutiny.
Where Tirzepatide Compounding Stands
The FDA's shortage determination ended the exemption that let 503A pharmacies and 503B outsourcing facilities compound tirzepatide without an individualized clinical justification. On April 30, 2026, the agency proposed to keep tirzepatide, semaglutide, and liraglutide off the 503B Bulks List permanently, finding no clinical basis for outsourcing facilities to compound them from bulk substances when FDA-approved versions are available. The comment period closed July 30, 2026, after a 30-day extension, and the FDA has not issued a final rule. The proposal targets 503B outsourcing facilities directly; 503A pharmacies remain bound by the patient-specific prescription requirement that separates the two pathways, covered in 503A vs 503B: Which Framework Governs Your Compounding.
Eli Lilly's Litigation Campaign Against Compounders
Eli Lilly filed suit in April 2025 against Strive Pharmacy in Delaware federal court and a second Texas-based compounding pharmacy in New Jersey federal court, and separately sued four telehealth platforms, Fella Health, Willow Health, Henry Meds, and Mochi Health, in the Northern District of California. The core allegation across the filings is that mass-produced compounded tirzepatide is marketed as personalized medicine, trading on Lilly's FDA-approved brand credibility without the safety and efficacy testing behind it. In January 2026, Strive countersued Lilly and Novo Nordisk, alleging antitrust conduct through exclusive agreements that barred telehealth platforms from working with compounding pharmacies. None of the matters has reached final judgment.
Every dispensing record now doubles as litigation evidence: the same documentation that satisfies a state inspector is the documentation a manufacturer's litigation team will request in discovery.
FDA Warning Letters and the Essentially-a-Copy Test
The FDA has issued more than 135 warning letters to GLP-1 compounders since September 2025, a count that continues to grow. Inspectors are applying the essentially-a-copy restriction with particular attention to two failure points: formulations that add unapproved ingredients to tirzepatide without a documented, patient-specific clinical rationale, and marketing language that describes mass-produced batches as personalized compounds. The same shortage-to-restriction pattern played out with semaglutide roughly a year earlier, detailed in Compounding Semaglutide After the Shortage Delisting: The Legal Landscape. A Form 483 finding on either failure point can trigger an FDA warning letter, a state board referral, or both.
The Compliance Posture That Reduces Exposure
A defensible compounding practice for tirzepatide starts with a documented, patient-specific clinical justification for every formulation, not a standing protocol applied across a patient population. Marketing and patient-facing materials should describe the compound accurately, without language implying FDA approval or clinical equivalence to Mounjaro or Zepbound. Outsourcing facilities operating under 503B should plan for the Bulks List exclusion to take effect rather than wait for a final rule. The same documentation discipline applies to adjacent GLP-1 and peptide compounds under review, a pattern examined in Peptide Compounding: Regulatory Status and the Gray Market. This posture narrows exposure to what the facts can support. It is not a guarantee of an outcome in an FDA inspection or civil litigation.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a Form 483 inspection finding, an FDA warning letter, a state board inquiry, or a civil complaint from a manufacturer. Early legal intervention can protect the pharmacy's rights, shape the response to the government or manufacturer's request, avoid inadvertent admissions, and preserve the defenses available under the applicable compounding framework. Delaying legal representation can significantly affect the outcome of a matter.
How Health Law Alliance Can Help
Health Law Alliance defends compounding pharmacies against FDA enforcement, state board referrals, and manufacturer litigation tied to tirzepatide and other GLP-1 compounds. The firm represents 503A and 503B facilities nationwide on Form 483 responses and Bulks List compliance. If your pharmacy has received an inspection finding, a warning letter, or a manufacturer complaint, contact us for a free, confidential consultation.
